Moreover, patients with KRAS mutation had favorable clinical benefits of anti-PD-1/PD-L1 immunotherapy [22], and high PD-L1 expression in tumor cells was associated with improved overall survival in KRAS mutant patients [23]. This evidence concerns the gene CD274 and neoplasm.